NNEWSLIVE
HomeBusinessOral Small-Molecule Therapies Versus Biologic Agents in Moderate-to-Severe Ulcerative Colitis: A Systematic Review of Pivotal Phase 3 Trials
Business

Oral Small-Molecule Therapies Versus Biologic Agents in Moderate-to-Severe Ulcerative Colitis: A Systematic Review of Pivotal Phase 3 Trials

Oral small-molecule therapies show promise in treating ulcerative colitis, but how do they compare to biologic agents in phase 3 trials?

E
Editorial Team
May 24, 2026
1 min read
Enter your email address to receive your free PDF download. Please note that by doing so you agree to be added to our monthly email newsletter distribution list. Yes, sign me up for the Cureus monthly newsletter. You can unsubscribe anytime.

Comments

Sign in to join the conversation

Sign In

No comments yet. Be the first to share your thoughts!

E
Written by

Editorial Team

Staff writer covering breaking news, features, and long-form analysis for NewsLive. Tracking the stories that matter most.

Stay in the loop

Get the best stories
delivered weekly

Join thousands of readers who get our top stories in their inbox every week. No spam, unsubscribe any time.